glp-1 shortage over The drug is over. What's next for the compounders? Paving the way for expanded

Trial reports describe a profile broadly consistent with incretin-based therapies, with gastrointestinal effects commonly noted, often during dose escalation

Patients have reported decreased interest in alcohol and nicotine when taking GLP-1s, and observational studies have shown an association between treatment with GLP-1 medication and lower risk of alcohol and cannabis use disorders, opioid overdose, and alcohol-related hospitalization

[Crossref] Romero-Gomez M, Boza F, Aguilar-Reina J (2001) Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy

Phasellus sed pharetra risus